MRNS Stock Overview
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders.
Marinus Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.02|
|52 Week High||US$13.15|
|52 Week Low||US$3.95|
|1 Month Change||-28.34%|
|3 Month Change||-39.18%|
|1 Year Change||-63.72%|
|3 Year Change||-43.54%|
|5 Year Change||-87.56%|
|Change since IPO||-87.44%|
Recent News & Updates
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue ForecastsOct 26
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?Oct 12
Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging HigherAug 13
Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) RevenuesMar 27
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?Mar 03
Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?Nov 04
We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash WiselyApr 14
Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share PriceMar 10
Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?Jan 07
|MRNS||US Pharmaceuticals||US Market|
Return vs Industry: MRNS underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: MRNS underperformed the US Market which returned -20.6% over the past year.
|MRNS Average Weekly Movement||10.4%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: MRNS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MRNS's weekly volatility (10%) has been stable over the past year.
About the Company
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Marinus Pharmaceuticals, Inc. Fundamentals Summary
|MRNS fundamental statistics|
Is MRNS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRNS income statement (TTM)|
|Cost of Revenue||US$74.11m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.29|
|Net Profit Margin||-71.31%|
How did MRNS perform over the long term?See historical performance and comparison